<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>See bel0ow for info from Michael Dean following up on his discussion at the support group meeting last week.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Michael Dean [mailto:mdean@ca.inter.net] <br><b>Sent:</b> March 4, 2019 11:29 AM<br><b>To:</b> 'Glen Tolhurst'<br><b>Cc:</b> mdean@ca.inter.net<br><b>Subject:</b> Clinical Trial - PET Scans<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Glen, <o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Sorry I have taken so long to get back to you with info on the things I discussed at the recent meeting. Last week turned out unexpectedly busy for me. I had a minor car accident on my way home from the meeting. Someone had inadvertently bumped into my driver’s door mirror in the parking lot which then folded in. I didn’t notice it and made a lane change bumping another vehicle. Necessitated getting quotes, reporting to police and all that stuff.<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>The Clinical trial that allowed me to get the PET Scan at St. Joseph’s in Hamilton is called: <i>PSMA-Based 18F-DCFPyL PET/CT: Evaluating its Application in REAL Life (PEARL)</i>. The principal Investigator at SJCC is a Dr. Katherine Zukotynski at SJHH. <u>Co-Investigator at GRCC is Dr. Joda Kuk.<o:p></o:p></u></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>The study’s purpose is to evaluate the relative effectiveness of this specific imaging technique compared to conventional CAT/Bone scans. These scans are also included in the trial unless you have had recent scans (within 8 weeks). <o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>There seem to be no special requirements other than having mPCa. 12 patients are to be enrolled through GRCC, of which I was the first. The document states that this is a pilot study to determine the number of participants that will be needed in a further trial.<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>I am also sending you links to a couple of the PSMA-617 Lutetium-177 treatment papers.<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>http://<a href="http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=29473">www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=29473</a><o:p></o:p></p><p class=MsoNormal>http://<a href="http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=29473">www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=29483</a><o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Cheers, <o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Michael Dean<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p></div></body></html>